Michel Fabbro

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 25

Top Topics

Prognostic Factors

Top Venues

Nature communications

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Elisa Yaniz-Galende, Qinghe Zeng, Juan Francisco Grau Bejar, Christophe Klein, Félix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle L Ray-Coquard, Florence Joly Lobbedez, Gwenaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Elisa Yaniz-Galende, Qinghe Zeng, Juan Francisco Grau Bejar, Christophe Klein, Félix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle L Ray-Coquard, Florence Joly Lobbedez, Gwenaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Elisa Yaniz-Galende, Qinghe Zeng, Juan Francisco Grau Bejar, Christophe Klein, Félix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle L Ray-Coquard, Florence Joly Lobbedez, Gwenaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
Spatial profiling of ovarian carcinoma and tumor microenvironment evolution under neoadjuvant chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Elisa Yaniz-Galende, Qinghe Zeng, Juan Francisco Grau Bejar, Christophe Klein, Félix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle L Ray-Coquard, Florence Joly Lobbedez, Gwenaël Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (13) (2024)
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, Michele Lamuraglia
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature communications 15 (1) (2024)
Julie A Vendrell, Iulian O Ban, Isabelle Solassol, Patricia Audran, Simon Cabello-Aguilar, Delphine Topart, Clothilde Lindet-Bourgeois, Pierre-Emmanuel Colombo, Eric Legouffe, Veronique D'Hondt, Michel Fabbro, Jean-Marc Rey
Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. International journal of molecular sciences 24 (18) (2023)
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, Andrés Redondo, Michel Fabbro, Bobbie J Rimel, Jørn Herrstedt, Amit M Oza, Ulrich Canzler, Jonathan S Berek, Antonio Gonzáles Martin, Phillipe Follana, Rosemary Lord, Masoud Azodi, Kasey Estenson, Zebin Wang, Yong Li, Divya Gupta, Ursula A Matulonis, Bin Feng
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer research communications 2 (11) (2022)
Paul Lesueur, Gandhi Laurent Damaj, Khê Hoang-Xuan, Virginie Roland, Anna Schmitt, Olivier Louis Chinot, Michel Fabbro, Philippe Agapé, Cécile Moluçon-Chabrot, Safia Chebrek, Agusti Alentorn, Loic Feuvret, Daniel Delgadillo, Dinu Stefan, Sylvain Choquet, Lucia Nichelli, Karima Mokhtari, Bertrand Mathon, Sylvain Dureau, Carole Soussain, Caroline Houillier
Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood advances 6 (16) (2022)
Mansoor Raza Mirza, Gabriel Lindahl, Sven Mahner, Andrés Redondo, Michel Fabbro, Bobbie J Rimel, Jørn Herrstedt, Amit M Oza, Ulrich Canzler, Jonathan S Berek, Antonio Gonzáles Martin, Phillipe Follana, Rosemary Lord, Masoud Azodi, Kasey Estenson, Zebin Wang, Yong Li, Divya Gupta, Ursula A Matulonis, Bin Feng
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects. Cancer research communications 2 (11) (2022)
Mathias Neron, Arnaud Guille, Lucie Allegre, Pierre-Emmanuel Colombo, Cristina Leaha, José Adelaide, Nadine Carbuccia, Frédéric Courtier, Florence Boissière, Evelyne Lopez-Crapez, Michel Fabbro, Sébastien Gouy, Emilie Mamessier, Éric Lambaudie, Daniel Birnbaum, François Bertucci, Max Chaffanet
Investigation of Molecular Features Involved in Clinical Responses and Survival in Advanced Endometrial Carcinoma Treated by Hormone Therapy. Journal of personalized medicine 12 (5) (2022)
Jean-David Fumet, Emilie Lardenois, Isabelle L Ray-Coquard, Philipp Harter, Florence Joly, Ulrich Canzler, Caroline Truntzer, Olivier Tredan, Clemens Liebrich, Alain Lortholary, Daniel Pissaloux, Alexandra Leary, Jacobus Pfisterer, Alexandre Eeckhoutte, Felix Hilpert, Michel Fabbro, Christophe Caux, Jérôme Alexandre, Aurélie Houlier, Jalid Sehouli, Emilie Sohier, Rainer Kimmig, Bertrand Dubois, Dominique Spaeth, Isabelle Treilleux, Jean-Sébastien Frenel, Uwe Herwig, Olivia Le Saux, Nathalie Bendriss-Vermare, Andreas du Bois
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial. Cancers 14 (5) (2022)
Stanislas Quesada, Michel Fabbro, Jean-Marc Rey
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives. Cancers 14 (4) (2022)
Michel Fabbro, William Jacot, Marta Jarlier, Séverine Guiu, Véronique D'Hondt, Stéphane Pouderoux, Patrice Champoiral, Chloé Janiszewski, Isabelle Nicklès
Hypnosis on patients treated with adjuvant chemotherapy for breast cancer: A feasibility study. Cancer reports (Hoboken, N.J.) (2022)
Stanislas Quesada, Michel Fabbro, Jean-Marc Rey
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. Cancers 14 (5) (2022)
Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwenaël Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, Olivier Colomban
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (17) (2020)
Michel Fabbro, Pierre-Emmanuel Colombo, Cristina Marinella Leaha, Philippe Rouanet, Sébastien Carrère, François Quenet, Marian Gutowski, Anne Mourregot, Véronique D'Hondt, Isabelle Coupier, Julie Vendrell, Paul Vilquin, Pascal Pujol, Jean-Marc Rey, Caroline Mollevi
Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer. Cancers 12 (8) (2020)